文献速递中枢神经肿瘤放疗放疗物理与技术

治疗前空间感知磁共振成像放射组学可预测立体定向放射外科/放疗后远处脑转移

Pretreatment Spatially Aware Magnetic Resonance Imaging Radiomics Can Predict Distant Brain Metastases (DBMs) After Stereotactic Radiosurgery/Radiation Therapy (SRS/SRT).
PubMed 文献 · Adv Radiat Oncol · 2024-02-06

该回顾性队列纳入105例接受SRS/SRT的脑转移患者,利用治疗前多参数MRI和放疗剂量分布图提取等剂量区域放射组学特征。放射组学Cox模型预测DBM时间的c-index为0.63,联合临床特征达0.69,均优于临床特征模型的0.49;放射组学特征可将患者分为DBM风险显著不同的组(P=0.00007)。

要点

  • 放射组学特征预测DBM时间的c-index为0.63,临床特征为0.49,联合模型为0.69。
  • 放射组学特征可区分DBM风险显著不同的组(P=0.00007),临床特征不能。
  • 瘤周50%至75%等剂量区和GTV区域的放射组学特征对DBM预测最具预测性。

核心结论

  • 治疗前MRI和多等剂量ROI提取的放射组学特征可建模SRS/SRT后DBM时间,优于临床特征基线。
  • 作者认为首次利用SRS/SRT剂量图识别ROI并对瘤周和未靶向脑区进行放射组学分析。
  • 作者观察到瘤周环境可能与SRS/SRT治疗的脑转移DBM发生相关。
  • 作者的初步结果可能有助于识别有DBM发生倾向的患者并促使后续疾病管理改变。

研究设计与样本

  • 回顾性分析105例接受SRS/SRT的脑转移患者,治疗前有多参数MRI(T1、T1增强、T2、FLAIR)。
  • 通过放疗剂量分布图和GTV轮廓识别5个等剂量ROI,从每个MRI序列提取三维放射组学特征。
  • 收集患者体能状态、治疗病灶数、肿瘤体积和肿瘤分期等临床特征作为基线比较。
  • 使用Cox比例风险模型和Kaplan-Meier分析建模DBM发生时间。

主要发现

  • 放射组学特征训练的CPH模型平均c-index为0.63(SD 0.08),临床特征模型为0.49(SD 0.09)。
  • 联合放射组学和临床特征的CPH模型c-index为0.69(SD 0.08)。
  • 放射组学特征可将患者分为DBM时间显著不同的风险组(log-rank检验P=0.00007),临床特征不能。
  • 瘤周50%至75%等剂量ROI和GTV区域的放射组学特征对DBM预测最具预测性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic radiosurgery/radiation therapy (SRS/SRT) increasingly has been used to treat brain metastases. However, the development of distant brain metastases (DBMs) in the untreated brain remains a serious complication. We sought to develop a spatially aware radiomic signature to model the time-to-DBM development in a cohort of patients leveraging pretreatment magnetic resonance imaging (MRI) and radiation therapy treatment planning data including radiation dose distribution maps. METHODS AND MATERIALS: We retrospectively analyzed a cohort of 105 patients with brain metastases treated by SRS/SRT with pretreatment multiparametric MRI (T1, T1 postcontrast, T2, fluid-attenuated inversion recovery). Three-dimensional radiomic features were extracted from each MRI sequence within 5 isodose regions of interest (ROIs) identified via radiation dose distribution maps and gross target volume (GTV) contours. Clinical features including patient performance status, number of lesions treated, tumor volume, and tumor stage were collected to serve as a baseline for comparison. Cox proportional hazards (CPH) modeling and Kaplan-Meier analysis were used to model time-to-DBM development. RESULTS: CPH models trained using radiomic features achieved a mean concordance index (c-index) of 0.63 (standard deviation [SD], 0.08) compared with a c-index of 0.49 (SD, 0.09) for CPH models trained using clinical factors. A CPH model trained using both radiomic and clinical features achieved a c-index of 0.69 (SD, 0.08). The identified radiomic signature was able to stratify patients into distinct risk groups with statistically significant differences (P = .00007) in time-to-DBM development as measured by log-rank test. Clinical features were unable to do the same. Radiomic features from the peritumoral 50% to 75% isodose ROI and GTV region were most predictive of DBM development. CONCLUSIONS: Our results suggest that radiomic features extracted from pretreatment MRI and multiple isodose ROIs can model time-to-DBM development in patients receiving SRS/SRT for brain metastases, outperforming clinical feature baselines. Notably, we believe we are the first to leverage SRS/SRT dose maps for ROI identification and subsequent radiomic analysis of peritumoral and untargeted brain regions using multiparametric MRI. We observed that the peritumoral environment may be implicated in DBM development for SRS/SRT-treated brain metastases. Our preliminary results might enable the identification of patients with predisposition to DBM development and prompt subsequent changes in disease management.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Bae J, Mani K, Zabrocka E, et al. Pretreatment Spatially Aware Magnetic Resonance Imaging Radiomics Can Predict Distant Brain Metastases (DBMs) After Stereotactic Radiosurgery/Radiation Therapy (SRS/SRT). Adv Radiat Oncol. 2024. PMID: 38550363. doi:10.1016/j.adro.2024.101457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。